This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Exemestane
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW HIGH
At 20yo with intact HPG axis, intact estradiol, and no AAS use, there is zero indication. Exemestane has community use as a post-cycle therapy (PCT) AI and as a daily-low-dose lipid/body-comp tweak in TRT contexts — neither applies. Verdict flips to OPTIONAL-ADD only inside a documented TRT or AAS context where estradiol is measured high AND a non-steroidal AI failed or caused joint pain (exemestane's steroidal structure tends to spare joints vs anastrozole). Crashing estradiol is the dominant risk and irreversible-binding makes overshoot harder to back out of than non-steroidal AIs.
▸ Stacking deep dive
Used during AAS cycles to titrate estradiol. Should not be combined with another AI unless deliberately bridging.
▸ Sourcing deep dive
Rx-only in US; gray-market research-chem versions widely available via the AAS supply chain. Quality varies.
▸ Verdict change log
- 2026-06-05 — Initial verdict SKIP-FOR-NOW. No standalone use case at 20yo intact HPG. (stub)
▸ Open questions / gaps Open
- Whether the very-low-dose (12.5 mg EOD or M/W/F) "longevity AI" use case has any signal in non-AAS users (mostly anecdote, no RCT).
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.